Date published: 2025-10-21

1-800-457-3801

SCBT Portrait Logo
Seach Input

TTI2_BC019943 Inhibitors

TTI2_BC019943 inhibitors are a class of chemical compounds that specifically target and inhibit the function of the TTI2 protein, encoded by the gene BC019943. TTI2 is part of the TTT (Tel2-Tti1-Tti2) complex, which plays a crucial role in the stabilization and assembly of phosphatidylinositol 3-kinase-related kinases (PIKKs), a family of proteins involved in essential cellular processes such as DNA damage response, cell cycle regulation, and cellular stress responses. TTI2 serves as a scaffold protein that helps coordinate the proper folding and maturation of PIKKs, ensuring their stability and activity. Inhibiting TTI2 disrupts the formation and maintenance of the TTT complex, thereby affecting the assembly and functional regulation of PIKKs within the cell.

Structurally, TTI2_BC019943 inhibitors are designed to bind to specific domains of the TTI2 protein that are critical for its interaction with other components of the TTT complex or its associated kinases. By preventing these interactions, these inhibitors can destabilize the TTT complex, leading to impaired function of PIKKs. This inhibition can alter key cellular pathways, including those involved in responding to DNA damage and maintaining genomic stability. The study of TTI2_BC019943 inhibitors offers researchers a deeper understanding of how the TTT complex and its associated kinases are regulated at the molecular level. Furthermore, these inhibitors provide a valuable tool for exploring the broader impact of disrupting PIKK stability, allowing researchers to investigate the fundamental processes of cell cycle control, DNA repair, and the stress response pathways that rely on proper PIKK function and stabilization.

SEE ALSO...

Items 1 to 10 of 11 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Palbociclib

571190-30-2sc-507366
50 mg
$315.00
(0)

Inhibits CDK4/6 involved in cell cycle regulation, which can lead to reduced activity of TTI2 by limiting cell proliferation.

Oligomycin A

579-13-5sc-201551
sc-201551A
sc-201551B
sc-201551C
sc-201551D
5 mg
25 mg
100 mg
500 mg
1 g
$175.00
$600.00
$1179.00
$5100.00
$9180.00
26
(1)

Inhibits ATP synthase, reducing ATP levels, which may decrease TTI2 activity by limiting energy-dependent processes TTI2 requires.

Trichostatin A

58880-19-6sc-3511
sc-3511A
sc-3511B
sc-3511C
sc-3511D
1 mg
5 mg
10 mg
25 mg
50 mg
$149.00
$470.00
$620.00
$1199.00
$2090.00
33
(3)

Inhibits histone deacetylase, altering chromatin structure and potentially reducing TTI2 activity through changes in gene expression.

Wortmannin

19545-26-7sc-3505
sc-3505A
sc-3505B
1 mg
5 mg
20 mg
$66.00
$219.00
$417.00
97
(3)

Inhibits PI3K, which is part of signaling pathways that can impact TTI2's role in cell cycle progression.

Rapamycin

53123-88-9sc-3504
sc-3504A
sc-3504B
1 mg
5 mg
25 mg
$62.00
$155.00
$320.00
233
(4)

Inhibits mTOR, a kinase that can influence TTI2 activity through cell growth and metabolic signaling pathways.

Bortezomib

179324-69-7sc-217785
sc-217785A
2.5 mg
25 mg
$132.00
$1064.00
115
(2)

Proteasome inhibitor that can lead to reduced TTI2 activity by causing an accumulation of proteins that may disrupt its function.

Cyclosporin A

59865-13-3sc-3503
sc-3503-CW
sc-3503A
sc-3503B
sc-3503C
sc-3503D
100 mg
100 mg
500 mg
10 g
25 g
100 g
$62.00
$90.00
$299.00
$475.00
$1015.00
$2099.00
69
(5)

Inhibits calcineurin, which can decrease TTI2 activity by affecting pathways involved in cell cycle and division.

Mitomycin C

50-07-7sc-3514A
sc-3514
sc-3514B
2 mg
5 mg
10 mg
$65.00
$99.00
$140.00
85
(5)

Alkylates DNA, potentially inhibiting TTI2 by interfering with the DNA-related processes TTI2 is involved in.

Camptothecin

7689-03-4sc-200871
sc-200871A
sc-200871B
50 mg
250 mg
100 mg
$57.00
$182.00
$92.00
21
(2)

Inhibits DNA topoisomerase I, which could decrease TTI2 activity by disrupting DNA replication where TTI2 may play a role.

Chloroquine

54-05-7sc-507304
250 mg
$68.00
2
(0)

Inhibits autophagy, which can lead to decreased TTI2 activity by impacting cellular degradation processes that involve TTI2.